HeraMED’s world-first telehealth device for maternal care

Telehealth has been growing in popularity over the years. There is, however, one area of health that has lagged behind – maternal care.

Telehealth has been growing in popularity over the years. There is, however, one area of health that has lagged behind – maternal care.

The basic standard of care continues to be centred around regular visits to the doctor. For a normal pregnancy, that adds up to around 14 visits. For a high risk pregnancy, that number can be as high as 40 visits. All of those trips to the doctor can get expensive and physically taxing.

The lack of maternal telehealth has mainly been due to a lack of reliable at-home technology to monitor the health of a pregnancy. The pandemic, however, was a catalyst for this, as pregnant women were encouraged to limit visits to their doctors to avoid COVID-19 exposure. 

HeraMED Limited (ASX: HMD) has a world-first solution that delivers personalised, proactive care to mother and baby from the comfort of home. 

“Now that everyone has got comfortable with using telehealth technology, and witnessed its benefits, there’s no going back. This obviously creates a significant tailwind to our business model and unique offerings,” said David Groberman, CEO and Co-Founder of HeraMED.

At the core of HeraMED’s business is the proprietary smart medical device, the HeraBEAT. 

The device enables monitoring of the fetal and maternal heartbeats, the gold standard to assess the health of a pregnancy. 

HeraBEAT pairs with HeraCARE, a full-blown digital maternity management solution that connects with a suite of other medical devices and maternal care providers.

On the HeraCARE platform, the mother and healthcare providers can access all vital data including blood pressure, glucose levels, sleep patterns, and educational material from the medical research centre Mayo Clinic, with which HeraMED is collaborating.The device and platform also enable physicians to provide more optimised care and make more sound medical decisions based on relevant and accurate data.

HeraMED’s offerings reduce pregnant women’s visits to the clinic, saving time and money. The device costs just US $200 with a monthly software subscription fee of $50 for the full product suite. 

Last year, HeraMED’s technology underwent an independent study that demonstrated HeraBEAT achieve hospital grade accuracy for monitoring fetal and maternal heart rates. It also received excellent usability and user satisfaction scores by clinicians and pregnant women. 

Equipped with clinical approval and support from the medical community, HeraMED is launching two pilot programs in Australia and the US to solidify its strategic direction. 

In Australia, the pilot program will run through Joondalup Health Campus, part of the Ramsay Health Group, who provide care for 25,000 births annually. In the US, the pilot is with Obstetrics Medical Group, an affiliate of Mednax. Listed on the NYSE, with a market capitalisation of over US$2.2 billion, Mednax is one of the largest providers of women’s and children’s physician services in the U.S. via its network of over 2,300 physicians in 39 states and Puerto Rico. Mednax-affiliated clinicians and their practices provide vital care or diagnostics to 1 in 4 babies born in the U.S. 

“This stage is focused on making sure that the technology is fully integrated and aligned with the hospital’s internal processes and standard of care. I’m sure it will quickly evolve into a full scale commercial rollout,” said David.

HeraMED plans to expand across all of Australia, the US, Israel, and Europe to support tens of thousands of births. 

“Our strategy is to focus on commercial efforts on early adopters of telehealth in pregnancy, focused on demonstrating the unique advantage of offering a remote home based maternity care model,” said David.

“We have multiple ways of generating revenue within each relationship, which offers us the flexibility to structure opportunities for each account, and engagement,” he added.


David Groberman recently joined us for our fortnightly webcast ‘The Insider: Meet the CEOs’. This article summarises some of the information he shared with us during the session. You can watch a full recording below, or you can click here to book into our next session.

‘The Insider’ is a great way to hear directly from the CEOs of fast growing Australian businesses. You will get valuable insights to their industries and companies future prospects.


The Insider: Meet the CEOs – Event Details:

Date: Wednesday, 23rd June Time: 12pm AEST Format: Online, 2 x 15 minute presentations

This is a free event. Click here to book your spot.


Reach Markets does not assume responsibility for the accuracy or completeness of any information provided, and the views expressed are not reflective of Reach Markets position. Any advice contained within this presentation is general advice and does not consider your personal circumstance, you should consider whether it’s appropriate for you. 

The information we are giving you is for educational purposes only. “Investing is about understanding your risk” and every time you invest in the share market there is a risk of loss.

Past performance is not a reliable indicator of future performance.




This Week’s News


8 May 2024

BHP Xplor winner coming to the ASX


16 April 2024

Gold at record highs – so why aren’t gold stocks?


22 November 2023

Rare Earths Industry Review: Part 2

General Advice Warning

Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG)

including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.

Please click here to read our full warning.